logo
Book a meeting
Monopar Therapeutics

Monopar Therapeutics

Biotechnology, 1000 Skokie BLVD, Wilmette, Illinois, 60091, United States, 11-50 Employees

monopartx.com

  • facebook
  • twitter
  • LinkedIn

Who is MONOPAR THERAPEUTICS

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patient...

Read More

lock icon Get Full Access
map
  • 1000 Skokie BLVD, Wilmette, Illinois, 60091, United States Headquarters: 1000 Skokie BLVD, Wilmette, Illinois, 60091, United States
  • 2015 Date Founded: 2015
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from MONOPAR THERAPEUTICS

Monopar Therapeutics Org Chart and Mapping

Employees
Margarita Gusakova

Margarita Gusakova

Sr. Accounting and Reporting Manager

See Full Org Chart arrow
email-formate-icon
View Email Formats for Monopar Therapeutics
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding Monopar Therapeutics

Answer: Monopar Therapeutics's headquarters are located at 1000 Skokie BLVD, Wilmette, Illinois, 60091, United States

Answer: Monopar Therapeutics's official website is https://monopartx.com

Answer: Monopar Therapeutics's revenue is $5 Million to $10 Million

Answer: Monopar Therapeutics's SIC: 2834

Answer: Monopar Therapeutics has 11-50 employees

Answer: Monopar Therapeutics is in Biotechnology

Answer: Monopar Therapeutics contact info: Phone number: Website: https://monopartx.com

Answer: Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR202, an early-stage camsirubicin analog for various cancers.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access